Compound | Plasma/serum concentrations | Cross-reactivity in Roche assay | Likelihood of clinically significant cross-reactivity |
---|---|---|---|
Progesterone | • 0.2 – 1.4 ng/mL (males) [44] | 100% | High (assay target) |
• Up to 27 ng/mL (women) [44] | |||
5β-Dihydroprogesterone | Up to 0.8 ng/mL in adults [45] | 18.2% | Possible significant contribution for individuals with progesterone concentrations on the lower end of reference interval |
17-Hydroxyprogesterone | • 0.08 – 2.0 ng/mL (pediatric controls) [22] | 1.2% | Low, except in patients with 21-hydroxylase deficiency |
• Up to 1,005 ng/mL (21-hydroxylase deficiency) [22] | |||
Pregnanolone | Up to 17Â ng/mL in women [33] | 0.90% | Low |
Allopregnanolone | Up to 29Â ng/mL in women [33] | 0.82% | Low |
Medroxyprogesterone | Up to 100Â ng/mL following dosing in women [46] | 0.67% | Possible significant contribution for individuals with progesterone concentrations on the lower end of reference interval |
Corticosterone | • 0.18 – 2.0 ng/mL (18 years and younger) [24] | 0.54% | Low |
• 0.53 – 1.6 ng/mL (<18 years) [24] | |||
11-Deoxycortisol | • 0.17 – 1.8 ng/mL (pediatric controls) [22] | 0.39% | Low, except in patients following metyrapone challenge or who have 11β-hydroxylase deficiency |
• Up to 63 ng/mL (11β-hydroxylase deficiency) [22] | |||
• Up to 250 ng/mL (metyrapone challenge) [25] | |||
Nandrolone | Up to 5.16Â ng/mL in men following intramuscular injection [47] | 0.17% | Low |
Pregnenolone | Up to 3.27Â ng/mL in women [33] | 0.12% | Low |
Exemestane | Up to 441Â ng/mL in post-menopausal women [48] | 0.09% | Possible significant effect if progesterone measured near peak of exemestane plasma concentration |
Androstenedione | • Up to 0.86 ng/mL before onset of puberty [30] | 0.09% | Low |
 | • Up to 3.2 ng/mL in 21-hydroxylase deficiency [30] |  |  |